Insider Buying Spotted at VRTX and IFF

Vertex Pharmaceuticals CEO Reshma Kewalramani purchased 10,000 shares of VRTX for $3.9M, and International Flavors & Fragrances CEO J. Erik Fyrwald bought 15,300 shares for $993,714. Both companies are trading down on Friday, with VRTX off 0.1% and IFF down 1%.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) reported robust financial results for the second quarter ended June 30, 2025, with total revenue increasing 12% to $2.96 billion, driven by strong performance of its cystic fibrosis (CF) therapies and early contributions from the launches of ALYFTREK, JOURNAVX, and CASGEVY [1]. The company also reiterated its full year 2025 financial guidance, projecting revenue of $11.85 to $12 billion.

Key highlights of the quarter include:

- Revenue Growth: Total revenue increased 12% to $2.96 billion, with U.S. revenue up 14% to $1.85 billion and international revenue up 8% to $1.12 billion [1].
- Launch Contributions: The launches of ALYFTREK, JOURNAVX, and CASGEVY contributed to the revenue growth, with ALYFTREK approved in multiple markets and JOURNAVX showing strong initial uptake [1].
- Clinical Advancements: Vertex reported significant progress in its clinical pipeline, including the advancement of suzetrigine in diabetic peripheral neuropathy (DPN), zimislecel in type 1 diabetes (T1D), povetacicept in immunoglobulin A nephropathy (IgAN) and pMN, and inaxaplin in adult-onset myoclonic epilepsy (AMKD) [1].
- Leadership Transition: Dr. David Altshuler, M.D., PhD., the current Chief Scientific Officer (CSO), announced his intent to retire on August 1, 2026, and Mark Bunnage, D.Phil., SVP of Global Research, will assume the role of CSO effective February 1, 2026 [1].

Vertex's CEO, Reshma Kewalramani, M.D., expressed gratitude for Dr. Altshuler's contributions and highlighted Mark Bunnage's qualifications to lead the next wave of innovation at the company.

The company's financial guidance for the full year 2025 includes revenue of $11.85 to $12 billion, combined GAAP and non-GAAP R&D, AIPR&D, and SG&A expenses of $5.55 to $5.7 billion and $4.9 to $5.0 billion, respectively, and a non-GAAP effective tax rate of 20.5% to 21.5% [1].

In other news, Vertex Pharmaceuticals CEO Reshma Kewalramani purchased 10,000 shares of VRTX for $3.9M, while International Flavors & Fragrances CEO J. Erik Fyrwald bought 15,300 shares for $993,714. Both companies are trading down on Friday, with VRTX off 0.1% and IFF down 1%.

References:
[1] https://investors.vrtx.com/news-releases/news-release-details/vertex-reports-second-quarter-2025-financial-results